A Study of Treatment Patterns and Outcomes in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients

Abroad (travel likely)Recruiting

Conditions

Gastroenteropancreatic Neuroendocrine Tumor

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Novartis, East Hanover, New Jersey, United States

Study leads

Novartis Pharmaceuticals
Study Director
Novartis Pharmaceuticals

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.

GEP-NET · Gastroenteropancreatic Neuroendocrine Tumor · Gastroenteropancreatic Neuroendocrine Tumor Disease

Abroad (travel likely)RecruitingPHASE1

Iowa City, United States · Lexington, United States

An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.

Advanced Gastroenteropancreatic Neuroendocrine Tumor

Abroad (travel likely)RecruitingPHASE3

Shanghai, China · Tianjin, China

Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors

Neuroendocrine Tumors Unresectable · Neuroendocrine Tumor Metastatic · Gastroenteropancreatic Neuroendocrine Tumor

Abroad (travel likely)RecruitingPHASE1, PHASE2

Jacksonville, United States · Miami, United States

Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET

Somatostatin Receptor Positive (SSTR+) · Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)

Abroad (travel likely)RecruitingPHASE3

Scottsdale, United States · Fayetteville, United States